[Study of a programmed release preparation of betahistine mesylate in the treatment of Ménière's disease (author's transl)].
The efficacy/tolerance ratio of a new form of betahistidine salt was studied in patients with Ménière's disease or isolated tinnitus. The study was divided into two stages: first, a conventional open trial, then a comparative cross-over trial. Analysis of efficacy scores showed that the drug was clearly effective in relieving vertigo and associated symptoms and had no clinical or biochemical side-effects.
D000328:Adult; D000368:Aged; D001621:Betahistine / Q000008:administration & dosage* / Q000009:adverse effects; D002986:Clinical Trials as Topic; D003692:Delayed-Action Preparations; D005260:Female; D006801:Humans; D008297:Male; D008575:Meniere Disease / Q000188:drug therapy*; D008875:Middle Aged; D011725:Pyridines / Q000008:administration & dosage*
D003692:Delayed-Action Preparations; D011725:Pyridines; D001621:Betahistine
Etude d'une forme à libération programmée de mésilate de bétahistine dans le traitement de la maladie de Ménière.